During Thursday’s Current trade, Shares of Affymetrix, Inc. (NASDAQ:AFFX), gain 1.43% to $8.50.
Affymetrix (AFFX) introduces Axiom™ HLA Analysis software for automated, high-resolution human leukocyte antigen (HLA) typing from any genotyping dataset containing coverage of the extended major histocompatibility complex (MHC) region. The software’s unique imputation algorithm enables 4-digit HLA typing from genome-wide association studies (GWAS), combining genotyping and high-resolution HLA typing into a single assay.
HLA is the genomic region most highly associated with human disease and is part of the MHC. The human body uses HLA proteins to identify self as compared to non-self cells and to recognize cells that are infected. The recognition of these signals triggers an immune response. Many HLA disease associations have been stated over the years and this remains an important area of research.
Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia.
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), declined -1.24% to $37.52, during its current trading session.
Sarepta Therapeutics, Inc. ( SRPT), a developer of innovative RNA-targeted therapeutics, recently declared that it has priced an underwritten public offering of an aggregate of 3,250,000 million shares of its common stock at a price to the public of $39.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 487,500 shares of common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be about $127 million, not taking into account any exercise of the underwriters’ option to purchase additional shares. The offering is predictable to close on or about October 9, 2015, subject to customary closing conditions.
Credit Suisse and Morgan Stanley are acting as joint book-running managers for the offering. In addition, Needham & Company, Oppenheimer & Co. Inc., Robert W. Baird & Co., Roth Capital Partners and William Blair, are acting as co-managers for the offering.
Sarepta intends to use the net proceeds from the offering principally for product and commercial development, manufacturing, any business development activities and for general corporate purposes.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases.
Ares Capital Corporation (NASDAQ:ARCC), during its Thursday’s current trading session gained 0.13% to $15.40.
Ares Capital Corporation (ARCC) declared that it will report earnings for the third quarter ended September 30, 2015 on Wednesday, November 4, 2015 proceeding to the opening of the Nasdaq Global Select Market. Ares Capital Corporation invites all interested persons to attend its webcast/conference call at 12:00 p.m. (Eastern Time) to talk about its third quarter 2015 financial results.
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
